Q-Line Biotech Ltd. IPO

We are engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. Our company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of our Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

Our key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

We are research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. We leverage our R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for our certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, we undertake the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies. With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, we employed 19 personnel at our R&D laboratories, which constituted 5.25% of our total permanent employee strength.

Further, for the Make in India instruments, we are working on the following projects:
• Selectra Pro M: We are currently manufacturing the Selectra Pro M—a medium-throughput, fully automatic clinical chemistry analyser—in India under a technical collaboration with one of the European companies. This instrument has been successfully scaled up for commercial production and is already serving laboratories across multiple regions.
• Selectra Pro XL - Building on our partnership, we are developing “Make in India” prototype of Selectra Pro XL which is a high-throughput, fully automatic clinical chemistry analyser designed for large laboratories and hospital networks. The prototype in advanced stages of development and will undergo internal validation before moving to formal approval.
• Microlab 300 - This device is currently undergoing regulatory review and approval. Once cleared, it will expand our portfolio into the semi-automatic analyser market for clinical chemistry
• Medonic M20: we have completed the development of the Medonic M20 three-part haematology analyser prototype. This device has passed both the regulatory and quality approval. Currently our staff is undergoing the required training for manufacturing, and we expect the commercial production for this to go live in Q2 FY26-27.
• KC1 Delta: we have also developed a prototype of the KC1 Delta coagulation analyser. This instrument is currently under review with the relevant authorities and is expected to enter the market upon receipt of the requisite approvals.
• Innolyte: Demonstrating our in-house R&D capabilities, we have indigenously developed the Innolyte electrolyte analyser with commercial production started in March 2026.
• Slide Stainer - we have indigenously developed the slide stainer and currently we are in the process of evaluating the reuse of stains and the commercial production of this instrument is expected to go line in Q3 of FY26-27.
• Q-Count 5: Currently under development, will be our indigenous 5-part haematology analyser.